title: [Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis].
abstract: OBJECTIVE
  To study the therapeutic efficacy of Longqingpian combined with Levofloxacin on Type IIIA prostatitis.
  
  
  METHODS
  Eighty patients with Type IIIA prostatitis were equally randomized into a Longqingpian group and a Puleanpian group, both treated for 12 weeks. The former were given Longqingpian (once 6 tablets, twice a day) combined with Levofloxacin (once 0.2 g, twice a day) during the first 4 weeks, followed by Longqingpian alone (once 6 tablets, twice a day) for 8 weeks. The latter received Puleanpian (once 4 tablets, 3 times a day) combined with Levofloxacin (once 0.2 g, twice a day) in the initial 4 weeks, followed by Puleanpian alone (once 4 tablets, 3 times a day) for 8 weeks. Before and 4, 8, and 12 weeks after the treatment, all the patients were evaluated by The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and EPS examination.
  
  
  RESULTS
  After 4-week, 8-week and 12-week treatment, total score of NIH-CPSI, and the score of pain, voiding symptoms and the quality of life dropped significantly in both groups compared with pre-treatment (P < 0.05 or 0.01), so did the leukocyte count in EPS (P < 0.05). Compared with the 4-week treatment, total score of NIH-CPSI, and the score of pain, voiding symptoms and the quality of life were shown to be significantly different (P < 0.05) in the Longqingpian group from the 8-week and 12-week treatment, except the leukocyte count in EPS. However, there was no significant difference between the 8-week and 12-week treatment in any of the indexes (P > 0.05). Longqingpian effected significant differences in the above indexes (P < 0.05), while Puleanpian did not after the treatment (P > 0.05). And the lecithin Amato body analysis revealed no significant changes in EPS after the treatment in either group (P > 0.05).
  
  
  CONCLUSIONS
  Longqingpian combined with Levofloxacin is highly effective for Type IIIA prostatitis, by relieving pain and voiding symptoms, decreasing the leukocyte count in EPS and improving the life quality of the patients.
authors.affiliation: Reproductive Medicine Research Center, the First Affiliated Hospital of Xinjiang Medical University, 830054, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Xu
authors.forename: Xue-jun
authors.initials: XJ
authors.lastname: Shang
authors.forename: Xia
authors.initials: X
authors.lastname: Cai
authors.forename: Wen-hui
authors.initials: WH
authors.lastname: Teng
authors.forename: Yu-feng
authors.initials: YF
authors.lastname: Huang
mesh_terms: D000328:Adult; D002908:Chronic Disease; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use*; D008517:Phytotherapy; D011472:Prostatitis / Q000188:drug therapy*
chemical_list: D064704:Levofloxacin; D015242:Ofloxacin